ASPIRO

A phase 1/2, randomised, controlled, open-label, ascending-dose clinical study to evaluate the safety and preliminary efficacy of AT132, a gene therapy delivered by an adeno-associated virus serotype 8 (AAV8) vector, in patients with X-linked myotubular myopathy (XLMTM).